成人癫痫持续状态二线抗癫痫药物的疗效:系统评价与网状Meta分析
该系统评价与网状Meta分析纳入7项随机对照试验共780例年龄≥15岁的癫痫持续状态患者,比较磷苯妥英、拉考沙胺、左乙拉西坦、苯妥英、苯巴比妥和丙戊酸作为二线抗癫痫药物的疗效。主要结局为30分钟和60分钟无癫痫复发的癫痫终止,次要结局为药物相关不良事件,效应量以相对危险度(RR)及95%置信区间(CI)表示。结果显示丙戊酸、磷苯妥英、拉考沙胺和左乙拉西坦对比苯巴比妥的RR分别为0.67(95%CI 0.53-0.85)、0.66(95%CI 0.48-0.90)、0.62(95%CI 0.41-0.93)和0.69(95%CI 0.51-0.94),均达统计学显著,苯巴比妥在癫痫终止排名中最高;不良事件因药物选择未见显著减少,但苯巴比妥排名最低。几乎所有比较的证据确定性均为极低,需谨慎解读。
要点
- 7项RCT共780例年龄≥15岁癫痫持续状态患者,比较磷苯妥英、拉考沙胺、左乙拉西坦、苯妥英、苯巴比妥和丙戊酸作为二线抗癫痫药物。
- 丙戊酸对比苯巴比妥RR 0.67(95%CI 0.53-0.85)、磷苯妥英对比苯巴比妥RR 0.66(95%CI 0.48-0.90)、拉考沙胺对比苯巴比妥RR 0.62(95%CI 0.41-0.93)、左乙拉西坦对比苯巴比妥RR 0.69(95%CI 0.51-0.94),均达统计学显著,证据确定性均为极低。
- 苯巴比妥在癫痫终止的排名中最高。
- 不良事件方面,因抗癫痫药物选择未见显著减少,但苯巴比妥的不良事件排名最低。
- 几乎所有比较的证据确定性均为极低,作者认为需谨慎解读。
适用人群与场景
- 年龄≥15岁的癫痫持续状态患者,纳入随机对照试验。
研究设计与关键结果
- 研究类型为系统评价与网状Meta分析,纳入7项随机对照试验,共780例年龄≥15岁的癫痫持续状态患者,检索MEDLINE、CENTRAL、ClinicalTrials.gov和世界卫生组织国际临床试验平台检索门户,检索截止至2023年12月31日。
- 比较的二线抗癫痫药物包括磷苯妥英(fPHT)、拉考沙胺(LCM)、左乙拉西坦(LEV)、苯妥英(PHT)、苯巴比妥(PHB)和丙戊酸(VPA)。
- 主要结局为整合30分钟和60分钟无癫痫复发的癫痫终止,次要结局为抗癫痫药物相关不良事件,效应量以相对危险度(RR)及95%置信区间(CI)表示。
- 丙戊酸对比苯巴比妥RR 0.67(95%CI 0.53-0.85;证据确定性极低)、磷苯妥英对比苯巴比妥RR 0.66(95%CI 0.48-0.90;证据确定性极低)、拉考沙胺对比苯巴比妥RR 0.62(95%CI 0.41-0.93;证据确定性极低)、左乙拉西坦对比苯巴比妥RR 0.69(95%CI 0.51-0.94;证据确定性极低),均达统计学显著。
- 苯巴比妥在癫痫终止的排名中最高。
- 不良事件方面,因抗癫痫药物选择未见显著减少,但苯巴比妥的排名最低。
证据类型、等级与局限
- 证据类型为系统评价与网状Meta分析,纳入7项随机对照试验,采用频率学框架的多变量随机效应模型,并基于推荐分级的评估、制定与评价(GRADE)框架评估证据确定性。
- 几乎所有比较的证据确定性均为极低。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,苯巴比妥可能作为成人癫痫持续状态二线抗癫痫药物中对癫痫终止最有效的一种。
- 作者指出,几乎所有比较的证据确定性均为极低,需谨慎解读。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Status epilepticus (SE) is potentially life-threatening, however, it is unclear which antiepileptic drugs (AEDs) should be used as second-line AEDs.
OBJECTIVE: We conducted a network meta-analysis (NMA) of randomized controlled trials (RCTs) comparing multiple second-line AEDs for SE to investigate the efficacy of AEDs.
METHODS: We searched MEDLINE, CENTRAL, ClinicalTrials.gov, and World Health Organization International Clinical Trials Platform Search Portal and included RCTs for patients aged ≥15 years with SE on December 31, 2023. We compared multiple second-line AEDs for SE including fosphenytoin (fPHT), lacosamide (LCM), levetiracetam (LEV), phenytoin (PHT), phenobarbital (PHB), and valproate (VPA). The primary and secondly outcomes were termination of seizures integrating the absence of seizure recurrence at 30 min and 60 min, and adverse events associated with AEDs, respectively, with expressing as relative risk (RR) with a 95% confidence interval (CI). We conducted a NMA using frequentist-based approach with multivariate random effects, and assessed the certainty based on the Grading of Recommendations, Assessment, Development, and Evaluations framework.
RESULTS: Seven RCTs (n = 780) were included, and statistically significant difference was detected between VPA vs. PHB (RR, 0.67; 95% CI, 0.53-0.85; very low certainty), fPHT vs. PHB (RR, 0.66; 95% CI, 0.48-0.90; very low certainty), LCM vs. PHB (RR, 0.62; 95% CI, 0.41-0.93; very low certainty), and LEV vs. PHB (RR, 0.69; 95% CI, 0.51-0.94; very low certainty). Moreover, PHB was the highest in the ranking for termination of seizures. For adverse events, no significant reduction was observed owing to the selection of AEDs, although the ranking of PHB was the lowest.
CONCLUSIONS: PHB may have been the most effective for seizure termination as second-line AEDs in adult patients with SE. However, the certainty of almost all comparisons was "very low", and careful interpretation is essential.
参考来源
- Kishihara Y, Yasuda H, Kashiura M, et al. Efficacy of second-line anticonvulsant agents with adult status epilepticus: A systematic review and network meta-analysis. Am J Emerg Med. 2024. PMID: 38941904. doi:10.1016/j.ajem.2024.06.019
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。